v3.25.4
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Restructuring Reserve [Roll Forward]      
Beginning balance $ 2,120 [1] $ 1,988  
Provision [2] 1,092 1,987 $ 1,968
Utilization and other [3] (1,302) (1,856)  
Ending balance 1,910 [4] 2,120 [1] 1,988
Employee Termination Costs [Member]      
Restructuring Reserve [Roll Forward]      
Beginning balance 2,046 [1] 1,978  
Provision 684 1,152  
Utilization and other [3] (947) (1,083)  
Ending balance 1,783 [4] 2,046 [1] 1,978
Asset Impairment Charges [Member]      
Restructuring Reserve [Roll Forward]      
Beginning balance 0 [1] 0  
Provision 349 432  
Utilization and other [3] (349) (432)  
Ending balance 0 [4] 0 [1] 0
Exit Costs [Member]      
Restructuring Reserve [Roll Forward]      
Beginning balance 74 [1] 11  
Provision 59 403  
Utilization and other [3] (6) (341)  
Ending balance $ 127 [4] $ 74 [1] $ 11
[1] Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).
[2] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $691 million for 2025 (including charges of $920 million for our Realigning our Cost Base Program and credits of $288 million for our Manufacturing Optimization Program), (ii) charges of $1.8 billion for 2024 (including charges of $1.2 billion our Manufacturing Optimization Program and charges of $571 million for our Realigning our Cost Base Program) and (iii) charges of $1.5 billion for 2023 (including charges of $1.4 billion for our Realigning our Cost Base Program and charges of $3 million for our Transforming to a More Focused Company program, that we have substantially completed). For 2025 and 2024, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
[3] Other activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements.
[4] Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).